

# Dietary Protein Intake and Kidney Disease in Type 2 Diabetes: A Narrative Review

Xue Li, Rui Lan, Xiangjun Chen\*

Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

\*Author to whom correspondence should be addressed.

**Abstract:** Traditionally, low-protein diet (LPD) is considered an important treatment for chronic kidney disease (CKD), while high-protein diet (HPD) is deemed to exacerbate the progression of CKD. Target dietary protein intake (DPI) for people with diabetes and CKD stages 1-4 should be 0.8 g/kg per day by current guidelines, neither HPD nor LPD appears beneficial. However, data from the NHANES show that the current actually average consumption of protein in the United States is higher than the guidelines recommended amount. We reviewed the current evidences on the relationship between protein intake and renal disease in Type 2 diabetes mellitus (T2DM) patients with different renal function stages and found that in T2DM patients with CKD stages 1-2, HPD was not associated with the risk of renal disease progression, and LPD did not benefit for these patients. Therefore, perhaps we should not emphasize the importance of dietary protein intake intervention in patients with CKD stages 1-2. Besides, LPD may alleviate proteinuria in patients with CKD stages 3-5, despite the risk of malnutrition. This narrow review focuses on the potential consequences of HPD or LPD on kidney diseases, and it may provide a guidance for clinicians to manage protein intake when treating T2DM patients with different stages of CKD.

**Keywords:** Dietary protein intake; Type 2 diabetes mellitus; Chronic kidney disease; Renal disease progression.

**Cited as:** Li, X., Lan, R., & Chen, X. (2025). Dietary Protein Intake and Kidney Disease in Type 2 Diabetes: A Narrative Review. *Journal of Theory and Practice in Clinical Sciences*, 2, 6–16. Retrieved from <https://woodyinternational.com/index.php/jtpcs/article/view/147>

## 1. Introduction

The burden of chronic kidney disease (CKD) in patients with diabetes mellitus (DM) is high and rising. CKD has become the major cause of end-stage kidney disease (ESRD) in people with diabetes worldwide[1, 2]. At present, the management of CKD includes diet, exercise intervention, drug therapy, prevention and treatment of complications. And the regulation of protein intake occupies an important part in diet intervention. Current guidelines recommend a target dietary protein intake (DPI) for people with diabetes and CKD stages 1-4 is 0.8 g/kg per day, and for patients on dialysis should be 1.0-1.2g /kg/d to ensure adequate energy due to high protein consumption[3, 4]. However, recommendations on DPI in guidelines are mainly based on the evidences from researches focused on non-diabetic patients with CKD and animal studies. The appropriate DPI for diabetic patients is still controversial. In this narrow review, we summarized the current evidences on the relationship between protein intake and renal disease in DM, regarding different quantification of protein intake; different sources of protein intake and different CKD stage, in order to provide a guidance for clinicians to manage protein intake when treating patients with CKD.

## 2. Protein Intake Quantification

At present, quantity and sources of DPI were mainly assessed by indirect ways such as measure urinary urea or nitrogen excretion[5], a food diary, self-reporting food intake via 24-h dietary recall or food frequency questionnaire(FFQ) [6, 7]. However, urinary nitrogen measurement reflects the intake over only a few days before urine collection and provide no information about sources of DPI, and questionnaire-based methods are linked to both random and systematic error. Among them, the FFQ is the most commonly used to investigate food intake over extended periods of time. Although there isn't universal agreement on what constitutes a HPD or a LPD, most definitions state that HPD refers to daily protein providing more than 20% of total energy or DPI > 1.3g/kg per day; LPD refers to DPI < 0.8g/kg per day [3]. Besides, data from the NHANES defined that HPD was > 130 g/d

and > 86g/d in males and females respectively (90th percentile protein intake for males and females in NHANES II data). LPD was defined as 42g/d for males and 28g/d for females based on NHANES II data (10th percentile protein intake for males and females)[8].

### 3. Quantity of DPI and CKD in patients with T2DM

#### 3.1 HPD and CKD

Studies [9-12] suggest that HPD does not affect renal function in healthy adults, but it impairs non-diabetic adults with CKD [13, 14]. Partial studies were focused on Type 2 diabetes mellitus (T2DM) patients when studied the association of HPD with CKD. We summarized these studies, which was shown in Table 1.

A cross-sectional study[15] in 2003 found that higher protein intake [ $\geq 19\%$  E% (protein energy contribution, the same below)] was not associated with microalbuminuria in diabetes patients (Odds ratio [OR] 2.17; 95% confidence interval[CI], 0.96 - 4.90;  $P = 0.09$ ). Another 5-year follow-up study[16] retrospectively included 144 patients with T2DM (baseline eGFR:  $82 \pm 20$  mL/min/1.73 m<sup>2</sup>) and divided them into two groups: LPD (< 0.8 g/kg/d) and HPD (> 1.3 g/kg/d). They found no significant difference in eGFR (0.07 vs -0.41 mL/min/1.73 m<sup>2</sup>) or UAE (0.01 vs -0.03 mg/g Cr) between the two groups during the study period. As for randomized controlled trials (RCTs), HPD showed no adverse effects on renal function either among patients with preserved renal function (mean eGFR  $\geq 60$  mL/min/1.73 m<sup>2</sup>). Pomerleau et al. [17] found no significant changes in eGFR ( $118.2 \pm 28.2$  vs  $118.8 \pm 38.4$  mL/min/1.73 m<sup>2</sup>) or urine protein excretion ( $98 \pm 105$  vs  $100 \pm 115$   $\mu$ g/min) in obese T2DM patients (BMI > 27 kg/m<sup>2</sup>) after 3 weeks of HPD (2 g/kg/d). Luger et al. [18] enrolled 44 patients with normal renal function treated with insulin. After 12 weeks of dietary intervention with normal protein diet (NPD; 15% E%) and HPD (30% E%), they found that there was no significant difference in urinary protein excretion rate ( $92.3 \pm 299.9$  vs  $104.3 \pm 252.7$   $\mu$ g/min) or eGFR ( $68.5 \pm 18.9$  vs  $73.8 \pm 13.9$  mL/min/1.73 m<sup>2</sup>) between the two groups. It is possible that the follow-up period of the trial was insufficient to observe an impact. Therefore, another investigator[19] extended the study time to one year and investigate the effects of HPD (30% E%) and NPD (15% E%) on renal function in obese T2DM patients (BMI: 27-40kg/m<sup>2</sup>), there was no difference between the two groups in urinary protein excretion rate (-4.65 vs -4.51  $\mu$ g/min) or eGFR (1.98 vs 3.2 mL/min/1.73 m<sup>2</sup>) either. Besides, another 2-year follow-up RCT [20] of 294 patients with normal renal function found no statistically significant difference in serum creatinine ( $83.1 \pm 23.6$  vs  $78.5 \pm 22.0$   $\mu$ mol/l) or UACR (0.72 vs 0.57 mg/mmol) between the HPD (30% E%) and NPD (15% E%) groups, but only 6% participants in the HPD groups achieved the target protein intake, which may lead to an underestimation of the differences in renal function between the two groups.

In addition, 382 T2DM patients were included in a newly published Dutch prospective study[21] (baseline mean eGFR:  $78 \pm 24$  mL/min/1.73 m<sup>2</sup>, average protein intake:  $91 \pm 27$ g/d), researchers found that DPI was inversely associated with deteriorating renal function (Hazard ratio [HR] 0.62; 95% CI, 0.44 - 0.90) after a median 6 years of follow-up, and patients with an intake >163 g/d had a decreased hazard for renal function deterioration (HR 0.42; 95% CI, 0.18-1.00). Although generally well designed, studies above were limited by their insufficient participant adherence and inconsistent measurements of GFR and proteinuria, which may have a certain impact on the results.

Overall, the populations included above were predominantly T2DM patients with preserved renal function (mean eGFR  $\geq 60$  mL/min/1.73 m<sup>2</sup>), and results shows that the progression of renal disease was not associated with HPD. However, HPD may aggravate the renal burden in patients at higher risk of renal function deterioration. A nested case-control study[22] enrolled 4255 participants (1057 in the ESRD group; 3198 in the control group) with different ethnic backgrounds from American community, they found that individuals in the highest quartile of protein intake (1.96 g/kg/d) had significantly higher odds of having ESRD than those in the lowest quartile (0.47 g/kg/d) (OR=1.76; 95% CI, 1.04 - 2.77;  $P < 0.05$ ) among blacks with diabetes but not among whites with diabetes, suggesting that the effect of protein intake are more likely to be observed among individuals with metabolic disorders. Blacks are more susceptible to be obese and have diabetes, which known to contribute to dysregulated protein metabolism when compared to whites of similar BMI. More studies are needed to explore the association of DPI with people who had a higher risk of deterioration of renal function.

#### 3.2 LPD and CKD

In various studies, 0.6-0.8g/kg/d is the most frequently recommended target for patients who received LPD

intervention. Studies [23, 24] have shown that LPD could slow the progression to ESRD in non-diabetic adults with CKD. Evidences related the potential benefits of a LPD on T2DM patients are inconsistent, which were summarized in Table 2.

In a prospective study of 6213 patients with T2DM (mean baseline eGFR  $\geq 60$  mL/min/1.73 m<sup>2</sup>) [25], participants in the lowest tertile of total protein intake (0.36 g/kg/d) had an increased risk of CKD (OR:1.16; 95%CI, 1.05 - 1.30;  $P < 0.05$ ) compared with participants in the highest tertile (0.96 g/kg/d), suggesting that excessive restriction of protein intake is associated with higher risk of CKD. A total of 131 T2DM patients were enrolled in a RCT [26] (baseline eGFR:  $82 \pm 19$  vs  $85 \pm 23$  mL/min/1.73 m<sup>2</sup>), after at least 12 months of follow-up, the annual change in eGFR ( $-4.8 \pm 12$  vs  $-6.4 \pm 14$  mL/min/1.73 m<sup>2</sup>,  $P = 0.5$ ) or albuminuria ( $+1.2$  vs  $+0.1$  mg/24h,  $P = 0.09$ ) were not statistically different between LPD (0.8g/kg/d) and NPD (1.15  $\pm$  0.26g/kg/d) groups, but the achieved degree of protein restriction was disappointingly low. Similarly, a RCT [27] included 112 Japanese T2DM patients (baseline eGFR:  $61.1 \pm 23.7$  vs  $63.5 \pm 26.9$  mL/min/1.73m<sup>2</sup>) and followed for 5 years, found no statistically difference in annual change of eGFR between NPD (1.2 g/kg/d) and LPD (0.8 g/kg/d) groups ( $-5.8 \pm 5.7$  vs  $-6.1 \pm 6.5$  mL/min/1.73m<sup>2</sup>,  $P = 0.93$ ). Studies above have not confirmed that a LPD favorably impacts CKD trajectory in T2DM patients with preserved renal function (eGFR  $\geq 60$  mL/min/1.73 m<sup>2</sup>).

Conversely, many studies have shown a beneficial impact of LPD upon trajectory of renal function in T2DM patients with reduced renal function (eGFR  $< 60$  mL/min/1.73m<sup>2</sup>). A retrospective study [28] enrolled 449 diabetic kidney disease(DKD) patients (stage G4-5) found that patients in LPD group(0.67  $\pm$  0.04 g/kg IBW/d) had a lower incidence of renal replacement therapy initiation (HR: 0.4; 95%CI: 0.23, 0.70;  $P = 0.001$ ) compared with NPD group(1.02  $\pm$  0.09 g/kg IBW/d), but it might lead to an increased mortality in patients with malnutrition. In a prospective study [29] of 74 elderly patients ( $> 65$  years old) with DKD (G3b - G4), a significant reduction in decline of creatinine clearance was observed in the LPD group (0.7 g/kg/d) but not in controls (1.1 g/kg/d) over a 36-month follow up ( $2.4 \pm 0.2$  vs  $5.7 \pm 0.5$  mL/min/y, respectively;  $P < 0.05$ ). Besides, a significant reduction in proteinuria, low-grade inflammation, and oxidative stress was observed in the LPD group ( $P < 0.05$ ). A 12-month follow-up RCT [30] showed that LPD (0.6 g/kg/d) combined Ketoacid  $\alpha$  could reduce urinary protein level ( $2.8994 \pm 1.462$  vs  $4.77 \pm 2.12$ g/d,  $P < 0.05$ ) in DKD patients (G3-4) compared with NPD group but no difference observed in eGFR ( $29.19 \pm 9.13$  vs  $29.77 \pm 13.19$  mL/min/1.73 m<sup>2</sup>). Overall, the populations included above were primarily T2DM patients with reduced renal function (mean eGFR  $< 60$  mL/min/1.73 m<sup>2</sup>), and results shows that LPD may be beneficial for alleviating the albuminuria in them.

A meta-analysis [31] of 8 RCTs involving 519 diabetic patients and concluded that LPD was not associated with changes of GFR ( $P = 0.61$ ), but a decrease in proteinuria or albuminuria was observed in the LPD group (SMD: -0.69; 95% CI, 1.14-0.23;  $P = 0.003$ ;  $I^2=81.4\%$ ). Another meta-analysis [32] of 13 RCTs involving 779 DKD patients (baseline mean eGFR: 76mL/min/1.73 m<sup>2</sup>) found that LPD (0.6-0.8 g/kg/d) was associated with an improvement in GFR ( $5.82$ mL/min/1.73m<sup>2</sup>; 95%CI, 2.3-9.33;  $P < 0.05$ ) when diet compliance was fair, but proteinuria (-0.14 units; 95%CI, -0.74 - 0.46,  $P = 0.65$ ) were not differed between the LPD and control groups(1-1.6 g/kg/d). Another meta-analysis [33] has shown a differential effect of LPD upon CKD progression according to types of diabetes. Protein intake restriction was beneficial in non-diabetic and type 1 diabetic patients but not in those with T2DM. The subgroup analysis of a meta-analysis published in 2021 [34] found that in DM patients with CKD stages 1-3, there were no statistical differences in GFR decline between the LPD and control groups (weight mean difference [WMD] 7.33 mL/min/1.73 m<sup>2</sup>, 95% CI, -1.61-16.27;  $P = 0.11$ ;  $I^2 = 94\%$ ), although LPD group benefited from protein restriction by achieving a decreased proteinuria (standard mean difference [SMD] -0.96 units; 95%CI, -1.81 - -0.11;  $P = 0.03$ ;  $I^2 = 90\%$ ). It is worth noting that the heterogeneities in studies above were substantial for the results.

A number of factors are assumed to influence the effectiveness of LPD in researches above. Firstly, the results of the RCTs often affected by the compliance of participants to dietary intervention. As Koya et al [27] reported previously, no differences in actual protein intake between NPD and LPD groups during follow-up. And the difference in actual protein intake between LPD and the control group was only 0.08g/kg/d at 6-month follow-up in another RCT [26]. Similarly, no differences were found in actual protein intake between the two groups during the follow-up in the RCT of Dussol et al. [35]. When applied a best-case analysis in patients with good adherence, Dussol et al. observed no statistical difference in changes of renal function between the two groups either. And among patients not receiving antihypertensive treatment, the decrease in GFR is four to five times higher than in patients with antihypertensive treatment, suggesting that antihypertensive treatment may have blunted the putative role of protein restriction on renal disease progression. Besides, Kasiske et al. [36] pointed out that the beneficial effect of a LPD seemed to be significantly greater in smaller trials, suggesting possible publication bias.

Furthermore, the study populations' sizes, as well as durations of intervention and the target of protein restriction were highly variable across the meta-analyses, which may also lead to inconsistent results.

### 3.3 Mechanisms in protein intake impact kidney function

It was first noted in the isolated perfused frog kidney model that amino acids and peptides could increase blood flow to the kidneys in 1928. And intervention studies indicate that HPD induces short-term up-regulation of GFR[37]. HPD dilates the afferent arteriole, induced by the tubuloglomerular feedback mechanism and nitric oxide synthases at el., resulting in an increased glomerular filtration rate over a short period, which leading to increased TGF- $\beta$  release and subsequent progressive glomerular fibrosis and renal damage [37, 38]. The adverse impact of HPD on the kidneys in diabetics was also observed. Tuttle et al. [39] found that the renal hemodynamic response to an increase in plasma amino acid concentrations is augmented in diabetic patients with enlarged kidneys. Although acute high protein intake may lead to glomerular hyperfiltration which result in progressive renal damage, the long-term effects of chronic high protein intake still controversial. Lacroix et al. [40] found that there was no difference in renal function between HPD (50% E%) and controls (14% E%) groups in male rats after 6 months of follow-up. More longer-term studies are needed to confirm the association of HPD with renal function in T2DM patients.

Animal studies have shown that LPD could prevent the occurrence and slow down the progression of diabetic nephropathy by improving abnormal metabolic factors and hemodynamics through multiple mechanisms, including improvements in glomerular hypertension and capillary hypertrophy[37, 41]. In animal models of T2DM, researchers demonstrated that an LPD intervention could improve diabetes-induced renal damages by restoring autophagy through the suppression of mTORC1[42]. However, clinical studies have not consistently shown beneficial effects of the dietary intervention with an LPD for the preservation of renal function in diabetic patients, more studies are needed to further confirm the relationship between them.

## 4. Sources of DPI

Observational studies[43-45] have noted that plant protein (defined as protein from tofu/soybean curd, legumes, vegetables, fruits and whole and refined grains) are beneficial for non-diabetic patients with CKD, while intake of animal protein, especially processed red meat consumption, are associated with the incidence and progression of CKD.

Partial studies were focused on T2DM patients when studied the association of CKD with sources of DPI. Cross-sectional studies found that increased animal protein intake derived from processed meat and red meat were associated with the presence of microalbuminuria [46], while higher intake of vegetable protein was associated with a lower prevalence of renal function impairment among T2DM patients[47]. A large prospective study[45] enrolled 60,198 participants(35% of whom were diabetics) showed that increased red meat intake was strongly associated with ESRD risk in a dose-dependent manner (4th vs.1st quartile HR=1.40 [95% CI, 1.15 - 1.71;  $P < 0.001$ ]) after a mean follow-up of 15.5 years, and replacing red meat with other food sources of protein such as fish may reduce the incidence of ESRD. In another RCT with follow up over 4 years [48], significant improvements were observed in albuminuria ( $-0.15 \pm 0.039$  vs  $0.02 \pm 0.01$ g/d;  $P = 0.001$ ) and urinary creatinine ( $-1.5 \pm 0.9$  vs  $0.6 \pm 0.3$ g/d;  $P = 0.01$ ) by soy protein intake (35% animal, 35% soy-origin, and 30% vegetable proteins) compared with those in the control group (70% animal and 30% vegetable proteins). And previous studies[49, 50] have shown that compared with intake of plant protein, intake of animal protein causes an imbalance in the composition of the gut microbiome and has a pro-inflammatory profile, which may affect kidney function. Besides, high red meat intake has been linked to increased inflammation and oxidative stress[51]. Thus, Plant and fish protein may be a more reasonable choice than animal protein which from red meat or processed meat for patients with T2DM. Further studies are needed to determine the effect of protein type upon renal function in T2DM patients with different stages of CKD.

## 5. Conclusion

To the best of our knowledge, this is the first review for investigating the correlation between protein intake and renal disease in T2DM patients with different renal function stages, and we summarize the current literature on the potential consequences of HPD or LPD on kidney diseases, which may provide a reference for clinicians when

treating patients.

According to NHANES data[52], the current average protein consumption in the United States is estimated to be approximately 1.2-1.4 g/kg per day, which is higher than the recommended amount. And in our narrow review, we found that HPD was actually not associated with increased renal function deterioration in patients with preserved renal function ( $eGFR \geq 60 \text{ mL/min/1.73 m}^2$ ), and LPD did not provide a significantly benefit for these patients. Thus, among patients with preserved renal function, we need not to emphasize the importance of dietary protein intake intervention, maybe unrestricted DPI was not contraindicated as a part of T2DM management. Besides, DPI under 0.8g/kg/d may be beneficial for alleviating the albuminuria in T2DM patients with reduced renal function ( $eGFR < 60 \text{ mL/min/1.73 m}^2$ ), but the risk of malnutrition should be concerned. In addition, maybe it is a more reasonable choice for T2DM patients to intake protein from plant and fish due to processed red meat was associated with renal function impairment. Further studies are needed to investigate the association of DPI with renal disease progression in T2DM patients with different stages of CKD.

## Support

This work was supported by the First batch of key Disciplines On Public Health in Chongqing, the Technological Innovation and Application Development Project of Chongqing (cstc2019jscx-msxmX0207), the Chongqing Science and Health Joint Medical Research Project (2020FYXX141; 2018GDRCO04), the Innovative Funded Project of Chongqing Innovation and Retention Program (cx2019032) and the Chongqing Yong and Middle-aged Senior Medical Talents Studio (ZQNYXGDRCGZS2021001) and the National Natural Science Foundation of China (81870567).

## Disclosure

All the authors have declared no competing interest.

## References

- [1] Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, et al. Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014. *JAMA*. 2016;316:602-10.
- [2] Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving H-H, et al. Nephropathy in diabetes. *Diabetes Care*. 2004;27 Suppl 1:S79-S83.
- [3] KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. *Kidney Int*. 2020;98.
- [4] Reid Chassiakos, Y. L., Radesky, J., Christakis, D., Moreno, M. A., Cross, C., Hill, D., ... & Swanson, W. S. (2016). Children and adolescents and digital media. *Pediatrics*, 138(5).
- [5] Maroni BJ, Steinman TI, Mitch WE. A method for estimating nitrogen intake of patients with chronic renal failure. *Kidney Int*. 1985;27:58-65.
- [6] Hankin JH, Stram DO, Arakawa K, Park S, Low SH, Lee HP, et al. Singapore Chinese Health Study: development, validation, and calibration of the quantitative food frequency questionnaire. *Nutr Cancer*. 2001;39:187-95.
- [7] Willett WC, Sampson L, Stampfer MJ, Rosner B, Bain C, Witschi J, et al. Reproducibility and validity of a semiquantitative food frequency questionnaire. *Am J Epidemiol*. 1985;122:51-65.
- [8] Jameel N, Pugh JA, Mitchell BD, Stern MP. Dietary protein intake is not correlated with clinical proteinuria in NIDDM. *Diabetes Care*. 1992;15:178-83.
- [9] Halbesma N, Bakker SJL, Jansen DF, Stolk RP, De Zeeuw D, De Jong PE, et al. High protein intake associates with cardiovascular events but not with loss of renal function. *J Am Soc Nephrol*. 2009;20:1797-804.
- [10] Van Elswyk ME, Weatherford CA, McNeill SH. A Systematic Review of Renal Health in Healthy Individuals Associated with Protein Intake above the US Recommended Daily Allowance in Randomized Controlled Trials and Observational Studies. *Adv Nutr*. 2018;9:404-18.
- [11] Jakobsen LH, Kondrup J, Zellner M, Tetens I, Roth E. Effect of a high protein meat diet on muscle and cognitive functions: a randomised controlled dietary intervention trial in healthy men. *Clin Nutr*. 2011;30:303-11.

- [12] Devries MC, Sithamparapillai A, Brimble KS, Banfield L, Morton RW, Phillips SM. Changes in Kidney Function Do Not Differ between Healthy Adults Consuming Higher- Compared with Lower- or Normal-Protein Diets: A Systematic Review and Meta-Analysis. *J Nutr*. 2018;148:1760-75.
- [13] Knight EL, Stampfer MJ, Hankinson SE, Spiegelman D, Curhan GC. The impact of protein intake on renal function decline in women with normal renal function or mild renal insufficiency. *Ann Intern Med*. 2003;138:460-7.
- [14] Cirillo M, Cavallo P, Bilancio G, Lombardi C, Terradura Vagnarelli O, Laurenzi M. Low Protein Intake in the Population: Low Risk of Kidney Function Decline but High Risk of Mortality. *J Ren Nutr*. 2018;28:235-44.
- [15] Wrone EM, Carnethon MR, Palaniappan L, Fortmann SP. Association of dietary protein intake and microalbuminuria in healthy adults: Third National Health and Nutrition Examination Survey. *Am J Kidney Dis*. 2003;41:580-7.
- [16] Kaji A, Hashimoto Y, Kobayashi Y, Wada S, Kuwahata M, Yamazaki M, et al. Protein intake is not associated with progression of diabetic kidney disease in patients without macroalbuminuria. *Diabetes Metab Res Rev*. 2019;35:e3150.
- [17] Pomerleau J, Verdy M, Garrel DR, Nadeau MH. Effect of protein intake on glycaemic control and renal function in type 2 (non-insulin-dependent) diabetes mellitus. *Diabetologia*. 1993;36:829-34.
- [18] Luger M, Holstein B, Schindler K, Kruschitz R, Ludvik B. Feasibility and efficacy of an isocaloric high-protein vs. standard diet on insulin requirement, body weight and metabolic parameters in patients with type 2 diabetes on insulin therapy. *Exp Clin Endocrinol Diabetes*. 2013;121:286-94.
- [19] Larsen RN, Mann NJ, Maclean E, Shaw JE. The effect of high-protein, low-carbohydrate diets in the treatment of type 2 diabetes: a 12 month randomised controlled trial. *Diabetologia*. 2011;54:731-40.
- [20] Krebs JD, Elley CR, Parry-Strong A, Lunt H, Drury PL, Bell DA, et al. The Diabetes Excess Weight Loss (DEWL) Trial: a randomised controlled trial of high-protein versus high-carbohydrate diets over 2 years in type 2 diabetes. *Diabetologia*. 2012;55:905-14.
- [21] Oosterwijk MM, Groothof D, Navis G, Bakker SJL, Laverman GD. High-Normal Protein Intake Is Not Associated With Faster Renal Function Deterioration in Patients With Type 2 Diabetes: A Prospective Analysis in the DIALECT Cohort. *Diabetes Care*. 2022;45:35-41.
- [22] Malhotra R, Cavanaugh KL, Blot WJ, Ikizler TA, Lipworth L, Kabagambe EK. Higher protein intake is associated with increased risk for incident end-stage renal disease among blacks with diabetes in the Southern Community Cohort Study. *Nutr Metab Cardiovasc Dis*. 2016;26:1079-87.
- [23] Hahn D, Hodson EM, Fouque D. Low protein diets for non-diabetic adults with chronic kidney disease. *Cochrane Database Syst Rev*. 2018;10:CD001892.
- [24] Mandayam S, Mitch WE. Dietary protein restriction benefits patients with chronic kidney disease. *Nephrology (Carlton)*. 2006;11:53-7.
- [25] Dunkler D, Dehghan M, Teo KK, Heinze G, Gao P, Kohl M, et al. Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus. *JAMA Intern Med*. 2013;173:1682-92.
- [26] Pijls LTJ, de Vries H, van Eijk JTM, Donker AJM. Protein restriction, glomerular filtration rate and albuminuria in patients with type 2 diabetes mellitus: a randomized trial. *Eur J Clin Nutr*. 2002;56:1200-7.
- [27] Koya D, Haneda M, Inomata S, Suzuki Y, Suzuki D, Makino H, et al. Long-term effect of modification of dietary protein intake on the progression of diabetic nephropathy: a randomised controlled trial. *Diabetologia*. 2009;52:2037-45.
- [28] Tauchi E, Hanai K, Babazono T. Effects of dietary protein intake on renal outcome and mortality in patients with advanced diabetic nephropathy. *Clin Exp Nephrol*. 2020;24:119-25.
- [29] Giordano M, Ciarambino T, Castellino P, Cataliotti A, Malatino L, Ferrara N, et al. Long-term effects of moderate protein diet on renal function and low-grade inflammation in older adults with type 2 diabetes and chronic kidney disease. *Nutrition*. 2014;30:1045-9.
- [30] Hongyu Qiu, Fang Liu, Lijun Zhao, et al. Prospective randomised open trial of compound  $\alpha$ -ketoic acid combined with low protein diet to delay progression of type 2 diabetic nephropathy. *Journal of Sichuan University (Medical Science)*. 2012;43:425-8. doi:10.13464/j.scuxbyxb.2012.03.024. Chinese.
- [31] Pan Y, Guo LL, Jin HM. Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials. *Am J Clin Nutr*. 2008;88:660-6.
- [32] Nezu U, Kamiyama H, Kondo Y, Sakuma M, Morimoto T, Ueda S. Effect of low-protein diet on kidney function in diabetic nephropathy: meta-analysis of randomised controlled trials. *BMJ Open*. 2013;3.
- [33] Rughooputh MS, Zeng R, Yao Y. Protein Diet Restriction Slows Chronic Kidney Disease Progression in Non-Diabetic and in Type 1 Diabetic Patients, but Not in Type 2 Diabetic Patients: A Meta-Analysis of Randomized Controlled Trials Using Glomerular Filtration Rate as a Surrogate. *PLoS One*. 2015;10:e0145505.

- [34] Li Q, Wen F, Wang Y, Li S, Lin S, Qi C, et al. Diabetic Kidney Disease Benefits from Intensive Low-Protein Diet: Updated Systematic Review and Meta-analysis. *Diabetes Ther.* 2021;12:21-36.
- [35] Dussol B, Iovanna C, Raccach D, Darmon P, Morange S, Vague P, et al. A randomized trial of low-protein diet in type 1 and in type 2 diabetes mellitus patients with incipient and overt nephropathy. *J Ren Nutr.* 2005;15:398-406.
- [36] Kasiske BL, Lakatua JD, Ma JZ, Louis TA. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. *Am J Kidney Dis.* 1998;31:954-61.
- [37] King AJ, Levey AS. Dietary protein and renal function. *J Am Soc Nephrol.* 1993;3:1723-37.
- [38] Sllstr?m J, Carlstr?m M, Olerud J, Fredholm BB, Kouzmine M, Sandler S, et al. High-protein-induced glomerular hyperfiltration is independent of the tubuloglomerular feedback mechanism and nitric oxide synthases. *Am J Physiol Regul Integr Comp Physiol.* 2010;299:R1263-R8.
- [39] Tuttle KR, Bruton JL, Perusek MC, Lancaster JL, Kopp DT, DeFronzo RA. Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. *N Engl J Med.* 1991;324:1626-32.
- [40] Lacroix M, Gaudichon C, Martin A, Morens C, Math é V, Tom é D, et al. A long-term high-protein diet markedly reduces adipose tissue without major side effects in Wistar male rats. *Am J Physiol Regul Integr Comp Physiol.* 2004;287:R934-R42.
- [41] Kalantar-Zadeh K, Fouque D. Nutritional Management of Chronic Kidney Disease. *N Engl J Med.* 2017;377:1765-76.
- [42] Kitada M, Ogura Y, Suzuki T, Sen S, Lee SM, Kanasaki K, et al. A very-low-protein diet ameliorates advanced diabetic nephropathy through autophagy induction by suppression of the mTORC1 pathway in Wistar fatty rats, an animal model of type 2 diabetes and obesity. *Diabetologia.* 2016;59:1307-17.
- [43] Chen X, Wei G, Jalili T, Metos J, Giri A, Cho ME, et al. The Associations of Plant Protein Intake With All-Cause Mortality in CKD. *Am J Kidney Dis.* 2016;67:423-30.
- [44] Haring B, Selvin E, Liang M, Coresh J, Grams ME, Petruski-Ivleva N, et al. Dietary Protein Sources and Risk for Incident Chronic Kidney Disease: Results From the Atherosclerosis Risk in Communities (ARIC) Study. *J Ren Nutr.* 2017;27:233-42.
- [45] Lew Q-LJ, Jafar TH, Koh HWL, Jin A, Chow KY, Yuan J-M, et al. Red Meat Intake and Risk of ESRD. *J Am Soc Nephrol.* 2017;28:304-12.
- [46] Almeida JC, Zelmanovitz T, Vaz JS, Steemburgo T, Perassolo MS, Gross JL, et al. Sources of protein and polyunsaturated fatty acids of the diet and microalbuminuria in type 2 diabetes mellitus. *J Am Coll Nutr.* 2008;27:528-37.
- [47] Oosterwijk MM, Soedamah-Muthu SS, Geleijnse JM, Bakker SJL, Navis G, Binnenmars SH, et al. High Dietary Intake of Vegetable Protein Is Associated With Lower Prevalence of Renal Function Impairment: Results of the Dutch DIALECT-1 Cohort. *Kidney Int Rep.* 2019;4:710-9.
- [48] Azadbakht L, Atabak S, Esmailzadeh A. Soy protein intake, cardiorenal indices, and C-reactive protein in type 2 diabetes with nephropathy: a longitudinal randomized clinical trial. *Diabetes Care.* 2008;31:648-54.
- [49] Mafra D, Borges NA, Cardozo LFMdF, Anjos JS, Black AP, Moraes C, et al. Red meat intake in chronic kidney disease patients: Two sides of the coin. *Nutrition.* 2018;46:26-32.
- [50] Tomova A, Bukovsky I, Rembert E, Yonas W, Alwarith J, Barnard ND, et al. The Effects of Vegetarian and Vegan Diets on Gut Microbiota. *Front Nutr.* 2019;6:47.
- [51] Montonen J, Boeing H, Fritsche A, Schleicher E, Joost H-G, Schulze MB, et al. Consumption of red meat and whole-grain bread in relation to biomarkers of obesity, inflammation, glucose metabolism and oxidative stress. *Eur J Nutr.* 2013;52:337-45.
- [52] Moore LW, Byham-Gray LD, Scott Parrott J, Rigassio-Radler D, Mandayam S, Jones SL, et al. The mean dietary protein intake at different stages of chronic kidney disease is higher than current guidelines. *Kidney Int.* 2013;83:724-32.
- [53] Tay J, Thompson CH, Luscombe-Marsh ND, Noakes M, Buckley JD, Wittert GA, et al. Long-Term Effects of a Very Low Carbohydrate Compared With a High Carbohydrate Diet on Renal Function in Individuals With Type 2 Diabetes: A Randomized Trial. *Medicine (Baltimore).* 2015;94:e2181.
- [54] Jesudason DR, Pedersen E, Clifton PM. Weight-loss diets in people with type 2 diabetes and renal disease: a randomized controlled trial of the effect of different dietary protein amounts. *Am J Clin Nutr.* 2013;98:494-501.
- [55] Meloni C, Morosetti M, Suraci C, Pennafina MG, Tozzo C, Taccone-Gallucci M, et al. Severe dietary protein restriction in overt diabetic nephropathy: benefits or risks? *J Ren Nutr.* 2002;12.
- [56] Meloni C, Tatangelo P, Cipriani S, Rossi V, Suraci C, Tozzo C, et al. Adequate protein dietary restriction in diabetic and nondiabetic patients with chronic renal failure. *J Ren Nutr.* 2004;14:208-13.

- [57] Barsotti G, Cupisti A, Barsotti M, Sposini S, Palmieri D, Meola M, et al. Dietary treatment of diabetic nephropathy with chronic renal failure. *Nephrol Dial Transplant*. 1998;13 Suppl 8:49-52.
- [58] Zhu H-G, Jiang Z-S, Gong P-Y, Zhang D-M, Zou Z-W, Qian Z, et al. Efficacy of low-protein diet for diabetic nephropathy: a systematic review of randomized controlled trials. *Lipids Health Dis*. 2018;17:141.
- [59] Robertson L, Waugh N, Robertson A. Protein restriction for diabetic renal disease. *Cochrane Database Syst Rev*. 2007;CD002181.
- [60] Li X-F, Xu J, Liu L-J, Wang F, He S-L, Su Y, et al. Efficacy of low-protein diet in diabetic nephropathy: a meta-analysis of randomized controlled trials. *Lipids Health Dis*. 2019;18:82.



**Table1:** Summary of studies of high protein intake and kidney disease in type 2 diabetes

Study Reference	Type	Size	Duration	Mean eGFR (mL/min/1.73m <sup>2</sup> )	Mean proteinuria levels	Protein intake (g/kg/d or % of % of energy)	Variable and Outcome
Wrone et al.[15]	Cross-sectional	4223	-	HPD: Females: 99.8 ± 1.1 Males: 84.8 ± 0.9	ACR < 300g/mg	HPD: ≥ 19% E% LPD: < 11.7% E%	HPD was not associated with microalbuminuria.
Kaji et al.[16]	Retrospective study	144	5y	82 ± 20	UAE: 15(7-38.9mg/gCr)	HPD: >1.3g/kg/d LPD: <0.8g/kg/d	HPD was not associated with changes in eGFR or UAE ( <i>P</i> > 0.05 for all comparisons).
Malhotra et al.[22]	nested case-control study	1409	8y	-	-	HPD: 1.96g/kg/d LPD: 0.47 g/kg/d	HPD was associated with increased incidence of ESRD (4th vs. 1st quartile OR=1.76; 95%CI, 1.04 - 2.77; <i>P</i> <0.05) in blacks with diabetes but not in whites with diabetes.
Oosterwijk et al. [21]	Prospective cohort	382	6y	78 ± 24	-	1.22±0.33g/kg/d	Increased dietary protein was inversely associated with renal function deterioration (HR: 0.62; 95%CI, 0.44 - 0.90).
Pomerleau et al. [17]	RCT	12	3wk	118.2 ± 28.2	AER: 15-300ug/min	HPD: 2 g/kg/d	HPD was not associated with changes of eGFR(118.2 ± 28.2 vs 118.8 ± 38.4mL/min/1.73m <sup>2</sup> ) or albumin excretion rate(98 ± 105 vs 100 ± 115 ug/min) after HPD for 3 weeks.
Luger et al.[18]	RCT	44	12wk	≥ 90	AER: HPD: 65.9 ± 175.4 ug/min NPD: 60.8 ± 195.8 ug/min	HPD: 30%E% NPD: 15%E%	eGFR(68.5 ± 18.9 vs 73.8 ± 13.9 mL/min/1.73 m <sup>2</sup> ) and AER(92.3 ± 299.9 vs 104.3 ± 252.7µg/min) were not different between HPD and NPD groups.
Tay et al.[53]	RCT	115	12mo	HPD: 96 NPD: 92	-	HPD: 28%E% NPD: 15%E%	The changes of eGFR were not different between HPD and NPD groups(-4 vs -2 mL/min/1.73m <sup>2</sup> , <i>P</i> = 0.25).
Larsen et al.[19]	RCT	99	12mo	HPD: 70.2 NPD: 72.6	AER: HPD: 30ug/min NPD: 26.2ug/min	HPD: 30% E% NPD: 15%E%	The changes of eGFR(1.98 vs 3.2 mL/min/1.73m <sup>2</sup> ) or AER(-4.65 vs -4.51µg/min) were not different between groups, although protein intake measured by urea nitrogen was not significantly.
Jesudason et al.[54]	RCT	45	12mo	HPD: 98 ± 28 PD: 91 ± 30	AER: HPD: 41 ± 11ug/min NPD: 82 ± 13ug/min	HPD: 30%E%M NPD: 20%E%S	eGFR(97 ± 20 vs 90 ± 28mL/min/1.73m <sup>2</sup> ) and AER were not different between HPD and NPD groups.
Krebs et al.[20]	RCT	294	2y	≥60	UACR > 30mg/mmol	HPD: 30%E% NPD: 15%E% (µmol/l)	Serum creatinine (83.1 ± 23.6 vs 78.5 ± 22.0µmol/l) and UACR (0.72 vs 0.57mg/mmol) were not different between HPD and NPD groups.

T2DM, type 2 diabetes mellitus; ACR, urinary albumin-creatinine ratio; UAE, urinary albumin excretion; UACR, urine albumin: creatinine ratio; AER, albumin excretion rate; HPD, high protein intake; NPD, normal-protein intake; RCT, randomized controlled trial.

**Table 2:** Summary of studies of low protein intake and kidney disease in type 2 diabetes

Study Reference	Type	Size	Duration	Mean eGFR(mL/min/1.73m <sup>2</sup> )	Mean proteinuria levels	Protein intake (g/kg/d or % of energy)	Variable and Outcome
Tauchi et al. [28]	Retrospective study	449	1.7y	LPD: 19.7 ± 10.9 NPD: 29.1 ± 20.9	UACR ≥ 300mg/g	LPD: 0.67 ± 0.04 g/kg IBW/d NPD: 1.02 ± 0.09 g/kg IBW/d	LPD group had a lower incidence of renal replacement therapy initiation (HR:0.4; 95%CI, 0.23 - 0.70; P = 0.001) compared with NPD group, but might lead to increased mortality in patients with malnutrition.
Dunkler et al. [25]	Prospective cohort	6213	5.5y	71.61	UACR: 9.31 mg/mmol	VLPD: 0.36 g/kg/d NPD: 0.96 g/kg/d	VLPD had greater risk of incident CKD (HR:1.16; 95%CI: 1.05,1.30; P < 0.05) when compared with NPD group.
Giordano et al. [29]	Prospective cohort	74	36mo	15 ≤ eGFR < 45	Proteinuria: LPD: 2.4 ± 0.5g/d NPD: 2.3 ± 0.9g/d	LPD: 0.7 g/kg/d (6 days a week) NPD: 1.1 g/kg/d	Compared with NPD, LPD was beneficial to improve the creatinine clearance (2.4 ± 0.2 vs 5.7 ± 0.5 ml/min/y, P < 0.05) and proteinuria (1.1 ± 0.2 vs 2.4 ± 0.8g/d, P < 0.05).
Qiu et al. [30]	RCT	23	12mo	LPD: 31.3 ± 10.41 NPD: 36.75 ± 13.25	AER > 300 mg/d	LPD: 0.6 g/kg/d NPD: 0.8 g/kg/d	LPD combined Ketoacid α could alleviate albumin excretion rate (2.8994 ± 1.462 vs 4.77 ± 2.12g/d, P < 0.05) compared with NPD group but no difference observed in eGFR (29.19 ± 9.13 vs 29.77 ± 13.19 ml/min/1.73 m <sup>2</sup> ).
Koya et al. [27]	RCT	112	5y	LPD: 63.5 ± 26.9 NPD: 61.1 ± 23.7	-	LPD: 0.8g/kg/d NPD: 1.2 g/kg/d	The annual changes in eGFR were not different between NPD and LPD groups (-5.8 ± 5.7 vs -6.1 ± 6.5 ml/min/1.73 m <sup>2</sup> , P = 0.93).
Dussol et al. [35]	RCT	47 (37 with T2DM)	2y	LPD: 89 ± 27 NPD: 82 ± 21	AER: > 30mg/d	LPD: 0.8g/kg/d NPD: 1.2 g/kg/d	The changes in eGFR (-5 ± 15 vs -7 ± 11 ml/min/1.73 m <sup>2</sup> ) and AER (+114 ± 364 vs +156 ± 486mg/d) were not different between NPD and LPD groups with strict blood pressure control.
Meloni et al. [55]	RCT	69 (37 with T2DM)	12mo	LPD: 43.9 ± 4.7 NPD: 45 ± 5.1	-	LPD: 0.68 ± 0.21g/kg/d NPD: 1.39 ± 0.28 g/kg/d	The changes in eGFR were not different between LPD and NPD groups (6.15 ± 1.61 vs 6.26 ± 1.84ml/min/1.73 m <sup>2</sup> ) with strict blood pressure and glycemic control, and it may induce malnutrition.
Meloni et al. [56]	RCT	80 (56 with T2DM)	12mo	LPD: 43.9 ± 4.7 NPD: 45 ± 5.1	-	LPD: 0.8 g/kg/d NPD: 1.24 g/kg/d	There were no statistically significant differences in eGFR (5.78 ± 1.5 vs 6.03 ± 1.3 ml/min/1.73 m <sup>2</sup> ) between the LPD and NPD groups.
Barsotti et al. [57]	RCT	32 (10 with T2DM)	3.7y	creatinine clearance (ml/min) VLPD: 8.9 ± 5.6 LPD: 44.6 ± 12.8	-	VLPD: 0.3 g/kg/d LPD: 0.7g/kg/d NPD: No restriction	LPD group had a lower decline in creatinine clearance (-0.22 ± 0.21 vs -0.9 ± 0.62 ml/min, P < 0.001) per month compared with NPD group.
Pijlis et al. [26]	RCT	131	28mo	LPD: 82 ± 19 NPD: 85 ± 23	albuminuria: LPD: 21.2mg/d NPD: 20.5mg/d	LPD: 0.8g/kg/d NPD: 1.15 ± 0.26g/kg/d	After at least 12 months of follow-up, the annual change in eGFR (-4.8 ± 12 vs -6.4 ± 14 ml/min/1.73 m <sup>2</sup> , P = 0.5) and albuminuria (+1.2 vs +0.1 mg/24h, P = 0.09) were not statistically different between LPD and NPD groups, but poor patient compliance.
Pan et al. [31]	Meta-analysis	519 (8 RCT and 4 including T2DM)	12 ~ 24mo	LPD: 43.9 ± 4.7 ~ 82 ± 21 NPD: 45 ± 5.1 ~ 89 ± 27	-	LPD: 0.6 - 0.8 g/kg/d NPD: 1.27 g/kg/d	LPD was not associated with changes in GFR but may slightly improve proteinuria (SMD: -0.69; 95%CI, -1.14 - -0.23; P = 0.003; I <sup>2</sup> = 81.4%).
Li et al. [34]	Meta-analysis	506 (9 RCTs and 4 including T2DM)	4.5 ~ 60mo	-	-	LPD: 0.6 - 0.8 g/kg/d NPD: 1.29 g/kg/d	The subgroup analysis of patients with CKD stages 1-3 found no statistical differences in GFR decline between the LPD and NPD groups (WMD: 7.33ml/min/1.73m <sup>2</sup> , 95%CI, -1.61 - 16.27; P = 0.11;

							I2 = 94%), but LPD could improve proteinuria (WMD: -0.96 units, 95% CI, -1.81 - -0.11; P = 0.03).
Zhu et al. [58]	Meta-analysis	687(11 RCTs and 6 including T2DM)	2~60mo	LPD: 31.1 ± 10.41 ~ 131 ± 34 NPD: 36.75 ± 5.1 ~ 122 ± 26	-	LPD: 0.6-0.8 g/kg/d	Intake of LPD demonstrated no protective effect on diabetic nephropathy neither on improving GFR (1.59ml/min/1.73m <sup>2</sup> , 95% CI, -0.57 - 3.75; P = 0.15) nor proteinuria (SMD: -0.48, 95% CI, -1.7 - 0.74; P = 0.44) when compared with NPD.
Nezu et al. [32]	Meta-analysis	779(13 RCTs and 5 including T2DM)	3 ~60mo	76	-	LPD: 0.6-0.8 g/kg/d control group: 1-1.6 g/kg/d	LPD was not associated with changes in proteinuria (-0.14, 95% CI, -0.74 - 0.46; P = 0.65) but had a higher eGFR (5.82ml/min/1.73m <sup>2</sup> ; 95% CI, 2.3 - 9.33; P < 0.05) compared with control groups.

T2DM, type 2 diabetes mellitus; LPD, low-protein intake; VLPD, low-protein intake; NPD, normal-protein intake; UACR, urinary albumin-creatinine ratio; AER, albumin excretion rate; UAER, urinary albumin excretion rate; IBM, ideal body weight; RCT, randomized controlled trial; WMD, weight mean difference; SMD, standard mean difference.

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of Woody International Publish Limited and/or the editor(s). Woody International Publish Limited and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.